{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"A Kaplan-Meier curve would have been used to describe the distribution.","groups":[{"description":"CONSOLIDATION: Patients received VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.\n\nIn between courses of VLD, patients received LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.\n\nMAINTENANCE: Starting in the third year of therapy, patients received lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given IV\n\nLenalidomide: Given PO\n\nDexamethasone: Given PO or IV","id":"OG000","title":"Enzyme Inhibitor, Biological Therapy, Chemotherapy"}],"populationDescription":"The study was terminated, study endpoints were not reached.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Event Free Survival Rates by Land-mark Analysis","type":"PRIMARY"}